Format

Send to

Choose Destination
Trends Cell Biol. 2001 Nov;11(11):S44-51.

TGF-beta signaling in cancer--a double-edged sword.

Author information

1
Mt Zion Cancer Research Institute, University of California at San Francisco, San Francisco, CA 94143-0875, USA. rakhurst@cc.ucsf.edu

Abstract

Transforming growth factor (TGF) beta1 is a potent growth inhibitor, with tumor-suppressing activity. Cancers are often refractile to this growth inhibition either because of genetic loss of TGF-beta signaling components or, more commonly, because of downstream perturbation of the signaling pathway, such as by Ras activation. Carcinomas often secrete excess TGF-beta1 and respond to it by enhanced invasion and metastasis. Therapeutic approaches should aim to inhibit the TGF-beta-induced invasive phenotype, but also to retain its growth-inhibitory and apoptosis-inducing effects.

PMID:
11684442
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center